Date: 2016-03-30
Type of information: Nomination
Compound:
Company: Curevac (Germany)
Therapeutic area: Cancer - Oncology - Immunological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 30, 2016, CureVac announced the expansion of its external Scientific Advisory Board (SAB) to guide the company in this important period of extensive clinical development and in its portfolio prioritization process. The SAB now consists of 16 leading scientists across CureVac’s key therapeutic categories, which include cancer immunotherapy, prophylactic vaccines and protein replacement therapy. The SAB is chaired by Ralf Clemens, MD, who has a long-standing track record of vaccine development at major multinational companies. CureVac’s Scientific Advisory Board includes the following experts across the company’s core therapeutic categories: Prof. Carol J. Baker, MD, Professor of Pediatrics, Molecular Virology & Microbiology, Baylor College of Medicine, Houston; past-chair of the Advisory Committee on Immunization Practices (ACIP), president of the Infectious Diseases Society of America and the National Foundation for Infectious Diseases
Prof. Nina Bhardwaj, MD, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York City; elected member of the American Society of Clinical Investigation and the American Association of Physicians; senior editor of the AACR Cancer Immunology Research journal
Ralf Clemens, MD, Chair of the SAB, former Vice President/ Senior Vice President GSK Biologicals, Novartis Vaccines and Takeda Vaccines; advisor to the Bill & Melinda Gates Foundation and to the Africa Research Excellence Fund (AREF); member of CureVac’s Supervisory Board
Michel De Wilde, PhD, member of the Board of Directors of the Infectious Disease Research Institute (IDRI) and of VBI; former Senior Vice President R&D at Sanofi Pasteur and Vice President Research GSK Biologicals
Prof. Dirk Jäger, MD, Director of Medical Oncology at the University Hospital of Heidelberg, Germany; leader of the research group “Applied Tumor Immunity” at the German Cancer Research Center
Prof. Karim Fizazi, MD, Head of the Department of Cancer Medicine at the Institut Gustave Roussy, Villejuif, France; President of the French Study Group of Carcinomas of Unknown Primary and associate editor of the European Journal of Cancer
Christopher Karp, MD, Director of Global Health Discovery & Translational Sciences at the Bill & Melinda Gates Foundation
Prof. Michael P. Manns, MD, Director of the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School, Germany
Prof. Stanley Plotkin, MD, Emeritus Professor of the Wistar Institute and the University of Pennsylvania, and Adjunct Professor of the Johns Hopkins University; editor of the standard textbook “Vaccines”
Jean-Paul Prieels, PhD, Member of the Board of various Biotech companies including DNAlytics and Vaximm; former Senior Vice President R&D at GSK Biologicals
Prof. Hans-Georg Rammensee, PhD, Head of the Department of Immunology at the University of Tübingen, Germany
George R. Siber, MD, Chief Scientific Officer, ClearPath Vaccines Company and former Executive Vice President of Wyeth Pharma, CSO of Wyeth Vaccines and Director of the Massachusetts Biologic Laboratories
Prof. Daniel Speiser, MD, head of clinical tumor biology and immunotherapy group, Department of Oncology and Ludwig Cancer Research Center, University of Lausanne, Switzerland
Prof. Xiao-Ning Xu, MD, PhD, Chair in Human Immunology at the Imperial College London; previously Head of Novartis Vaccines Research China
Prof. Fred Zepp, MD, Medical Director and Chairman of the Department of Pediatrics, University Medical Center of the Johannes Gutenberg-University Mainz, Germany; past president of the German Society of Pediatrics and Adolescent Medicine; member of the STIKO at the Robert Koch Institute
Gerd Zettlmeissl, PhD, Chairman Hilleman Laboratories, Board of Directors of Aeras and board member of various Biotech companies; former Managing Director of Chiron Behring and Chief Executive Officer of Intercell.
Financial terms:
Latest news:
